Filing Details

Accession Number:
0001415889-25-006575
Form Type:
4
Zero Holdings:
No
Publication Time:
2025-03-04 16:58:32
Reporting Period:
2025-02-28
Filing Date:
2025-03-04
Accepted Time:
2025-03-04 16:58:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1346830 Cara Therapeutics Inc. CARA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1706426 Scott Terrillion C/O Cara Therapeutics, Inc.
400 Atlantic Street, Suite 500
Stamford CT 06901
Sec'y; Chief Compliance & G.c. No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2025-02-28 163 $4.76 7,190 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on September 7, 2018 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.
  2. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The total number of securities reported as beneficially owned following the reported transaction reflects the 1-for-12 reverse stock split that was effected by the Issuer on December 30, 2024.